Baird Reiterates Outperform on Instil Bio, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has reiterated an Outperform rating for Instil Bio (NASDAQ:TIL) and maintained a price target of $180.
September 16, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Jack Allen has reiterated an Outperform rating for Instil Bio and maintained a price target of $180, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by a reputable analyst suggests a positive outlook for Instil Bio. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100